Literature DB >> 7866641

Analysis of clonality by amplification of short tandem repeats. Carcinomas of the female reproductive tract.

T Enomoto1, M Fujita, M Inoue, O Tanizawa, T Nomura, K R Shroyer.   

Abstract

The clonal composition of cancers of the female reproductive tract was evaluated by analysis of patterns of X-chromosome inactivation. Using DNA extracted from frozen tissues or paraffin-embedded archival specimens as template, polymerase chain reaction (PCR) was performed to generate amplified DNA fragments of exon 1 of the X-linked androgen receptor gene, which contains a highly polymorphic trinucleotide repeat. Predigestion of tumor DNA with methylation-sensitive restriction endonuclease Hha I or Hpa II permitted selective PCR amplification from the methylated (uncleaved) allele. Of a total of 54 tumors analyzed, 50 cases showed heterozygosity (93%) and were therefore informative for clonal analysis. Monoclonal composition of the tumors was suggested in a total of 49 of 50 cases, including 12 adenocarcinomas of the uterine endometrium, 13 squamous cell carcinomas of the uterine cervix, 6 adenocarcinomas of the uterine endocervix, and 18 epithelial tumors of the ovary. However, polyclonal composition was observed in one mucinous carcinoma of the ovary, in which we previously showed that both GGT-->GAT and GGT-->GTT mutations are present in > 20% of total K-ras copies in the tissue. Our studies demonstrate the utility of PCR amplification of highly polymorphic repetitive sequences for analysis of patterns of X-chromosome inactivation. This approach is practical for the analysis of clonal cell composition in a high proportion of both formalin-fixed and frozen archival tissues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866641     DOI: 10.1097/00019606-199412000-00013

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  8 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium.

Authors:  Masaaki Tanaka; Satoru Kyo; Taro Kanaya; Noriyuki Yatabe; Mitsuhiro Nakamura; Yoshiko Maida; Masaru Okabe; Masaki Inoue
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

3.  Molecular analysis of clonality in Kaposi's sarcoma.

Authors:  E Delabesse; E Oksenhendler; C Lebbé; O Vérola; B Varet; A G Turhan
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

4.  Clonal analysis of focal nodular hyperplasia of the liver.

Authors:  M J Gaffey; J C Iezzoni; L M Weiss
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

5.  Clonality Analysis of Benign Parathyroid Lesions by Human Androgen Receptor (HUMARA) Gene Assay.

Authors:  Xavier Sanjuan; Bonita R. Bryant; Mark E. Sobel; Maria I. Merino
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

6.  Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.

Authors:  Kaori Shimazaki; Eric J Lepin; Bo Wei; Agnes K Nagy; Catherine P Coulam; Sergey Mareninov; Maoyong Fu; Anna M Wu; James D Marks; Jonathan Braun; Lynn K Gordon; Madhuri Wadehra
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

7.  Clonality analysis of synchronous lesions of cervical carcinoma based on X chromosome inactivation polymorphism, human papillomavirus type 16 genome mutations, and loss of heterozygosity.

Authors:  Xinrong Hu; Tianyun Pang; Anna Asplund; Jan Pontén; Monica Nistér
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

8.  Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA.

Authors:  Katrin Carow; Mandy Gölitz; Maria Wolf; Norman Häfner; Lars Jansen; Heike Hoyer; Elisabeth Schwarz; Ingo B Runnebaum; Matthias Dürst
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.